TOP2A as marker of response to pegylated lyposomal doxorubicin (PLD) in epithelial ovarian cancers

OBJECTIVE: Relapsed epithelial ovarian cancer (EOC) is frequently treated with pegylated liposomal doxorubicin (PLD). Unfortunately, most patients do not benefit from treatment. Prediction of response is crucial to optimize PLD use and avoid unnecessary toxicities. We aimed at assessing the value of...

Descripción completa

Detalles Bibliográficos
Autores principales: Ghisoni, Eleonora, Maggiorotto, Furio, Borella, Fulvio, Mittica, Gloria, Genta, Sofia, Giannone, Gaia, Katsaros, Dionyssios, Sciarrillo, Alberto, Ferrero, Annamaria, Sarotto, Ivana, Erriquez, Jessica, Di Renzo, Maria Flavia, Aglietta, Massimo, Valabrega, Giorgio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6373097/
https://www.ncbi.nlm.nih.gov/pubmed/30760286
http://dx.doi.org/10.1186/s13048-019-0492-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6373097/
https://www.ncbi.nlm.nih.gov/pubmed/30760286
http://dx.doi.org/10.1186/s13048-019-0492-6

Ejemplares similares